Tempol not checked
Matrix Biomed, Inc. · MBM-01 · MBM-02
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.”In the company’s words, NCT03480971 on ClinicalTrials.gov
- Tested for
- Mucositis, Nephrotoxicity, Ototoxicity
- Main trialPhase 2
- “A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.”In the company’s words, NCT03480971 on ClinicalTrials.gov
- Other names
- MBM-01 · MBM-02
Other drugs for Mucositis
- RRx-001EpicentRx, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2025 | Treatment of Radiation and Cisplatin Induced Toxicities with Tempol | |
| Phase 2Unknown | Jun 2022 | MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia | |
| Phase 2Unknown | Sep 2022 | MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer | |
| Phase 2Unknown | Jan 2023 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026